IONS Ionis / Roche: Sefaxersen Hits Phase 3 Primary Endpoint in IgA Nephropathy ⠀ · Interim Phase 3 showed statistically significant, clinically meaningful proteinuria reduction at Week 37. · Safety was consistent with prior studies, with no new signals; trial continues through Week 105. · Ionis remains eligible for regulatory and sales milestones plus tiered royalties on net sales.
IONS Ionis / Roche: Sefaxersen Hits Phase 3 Primary Endpoint in IgA Nephropathy ⠀ • Interim Phase 3 showed statistically significant, clinically meaningful proteinuria reduction at Week 37. • Safety was consistent with prior studies, with no new signals; trial continues through Week 105. • Ionis remains